Interesting – the generics are coming to biotech, but it is and will take some time. Part of the ongoing debate in pharmaceuticals on the appropriate balance between encouraging innovation through strong intellectual property protection (essentially guaranteeing monopoly-type profits for a number of years) and cost-effectiveness for healthcare systems.
